RWJ-50271

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameRWJ-50271

Drug Alias NameRWJ-50271

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionIntegrin alpha-L/beta-2 (LFA-1) antagonists

TargetsIntegrin alpha-L/beta-2 (LFA-1)

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesJohnson & Johnson

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

ATC CodeN/A